Targets › DCLRE1C
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Nov 2041.
Nuclease involved in DNA non-homologous end joining (NHEJ); required for double-strand break repair and V(D)J recombination. Required for V(D)J recombination, the process by which exons encoding the antigen-binding domains of immunoglobulins and T-cell receptor proteins are assembled from individual V, (D), and J gene segments. (UniProt, Q96SD1)
Open in Phaseline: the race on DCLRE1C, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | ARTEGENE Lentiviral vector-mediated ex vivo gene therapy delivering wild-type DCLRE1C cDNA to autol | DCLRE1C | Phase 1 | Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency | Nov 2041 |
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency (1)
other (1)
Assistance Publique - Hôpitaux de Paris (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.